Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children with Chronic Hepatitis B Virus Infection
收藏DataCite Commons2024-12-04 更新2025-04-16 收录
下载链接：
https://repository.niddk.nih.gov/studies/hbrn-immune-tolerant-p
下载链接
链接失效反馈官方服务：
资源简介：
The Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN Immune Tolerant P) sought to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B. Children age 3-<18 years with immunotolerant chronic hepatitis B (CHB) infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and then combination therapy with entecavir and pegylated interferon by weekly subcutaneous injection until week 48. Children were to be followed for 48 weeks after discontinuation of therapy.
提供机构：
NIDDK Central Repository
创建时间：
2024-12-03
